Pemvidutide elicited significant weight loss and decreases in pro-inflammatory serum lipids associated with atherogenesis and cardiovascular disease risk

GAITHERSBURG, MD, USA I June 22, 2024 I Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data on the effect of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate in development for obesity and metabolic dysfunction-associated steatohepatitis (MASH), on cardioinflammatory lipids at the American Diabetes Association’s (ADA) 84th Scientific Sessions.

“Dyslipidemia is one of the most significant co-morbidities of obesity, impacting up to 70% of patients with obesity,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “These data add to the differentiated profile of pemvidutide and reinforce its potential to reduce inflammatory lipids associated with cardiovascular plaque formation and cardiovascular risk in patients with obesity.”

Dysregulated lipid profiles in obesity can cause systemic inflammation and elevate cardiovascular disease (CVD) risk. To better understand the potential impact of pemvidutide on lipoprotein and glycoprotein biomarkers of CVD inflammation, samples were analyzed from the 12-week, randomized placebo-controlled Phase 1 study of pemvidutide in subjects with overweight or obesity but not type 2 diabetes. In the study, 34 subjects were randomly assigned 1:1:1:1 to pemvidutide (1.2mg, 1.8mg and 2.4mg) or placebo administered once-weekly subcutaneously for 12 weeks. Lipidomic, lipoparticle and glycoprotein profiling was conducted using ultra-high performance liquid chromatography-mass spectrometry and proton nuclear magnetic resonance on plasma samples at baseline and after 12 weeks of treatment.

Serum lipids including total cholesterol, low density lipoprotein cholesterol (LDL-C), and triglycerides were reduced by 28%, 26% and 38% respectively. The reductions in each class of these lipids were not correlated with weight loss, suggesting that lipid effects were due to the direct impact of pemvidutide on lipid metabolism. A detailed analysis showed pemvidutide significantly reduced small dense LDL-C, short-chain diglycerides with higher degree of saturation, lysophosphatidylinositols, lysophosphatidylcholines and sphingolipids, all lipids with a strong association with CVD. Reductions in GlycA and GlycB, biomarkers of systemic inflammation that are known to correlate with heart failure, were also observed. In addition to the reductions in weight and serum lipids, treatment with pemvidutide resulted in reductions to systolic and diastolic blood pressure across all dose groups, suggesting that pemvidutide may have pleiotropic effects that may contribute to decreased CVD risk.

About Pemvidutide

Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, which is believed to lead to rapid reductions in levels of liver fat and serum lipids. In clinical trials to date, once-weekly pemvidutide has demonstrated compelling weight loss, robust reductions in triglycerides, LDL cholesterol, liver fat content and blood pressure. The U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of MASH. Pemvidutide recently completed the MOMENTUM Phase 2 obesity trial and is being studied in the ongoing IMPACT Phase 2b MASH trial.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit

SOURCE: Altimmune